338 related articles for article (PubMed ID: 28930692)
1. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
Raphael J; Helou J; Pritchard KI; Naimark DM
Eur J Cancer; 2017 Nov; 85():146-154. PubMed ID: 28930692
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
[TBL] [Abstract][Full Text] [Related]
3. Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
Matter-Walstra K; Ruhstaller T; Klingbiel D; Schwenkglenks M; Dedes KJ
Breast Cancer Res Treat; 2016 Jul; 158(1):51-57. PubMed ID: 27277747
[TBL] [Abstract][Full Text] [Related]
4. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
Zhang B; Long EF
Breast Cancer Res Treat; 2019 Jun; 175(3):775-779. PubMed ID: 30847728
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR
Zhang Y; Zeng X; Deng H; Ma F; Peng Y; Yi L; Tan C; Peng L
Clin Ther; 2019 Jun; 41(6):1175-1185. PubMed ID: 31104762
[TBL] [Abstract][Full Text] [Related]
7. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab in the Treatment of Metastatic Renal Cell Carcinoma: A Cost-Utility Analysis.
Raphael J; Sun Z; Bjarnason GA; Helou J; Sander B; Naimark DM
Am J Clin Oncol; 2018 Dec; 41(12):1235-1242. PubMed ID: 29727313
[TBL] [Abstract][Full Text] [Related]
9. Palbociclib: first global approval.
Dhillon S
Drugs; 2015 Apr; 75(5):543-51. PubMed ID: 25792301
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.
Cameron D; Kumar Sharma V; Biswas C; Clarke C; Chandiwana D; Pathak P
J Med Econ; 2023; 26(1):357-365. PubMed ID: 36797664
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK.
Nuijten M; Meester L; Waibel F; Wait S
Pharmacoeconomics; 1999 Oct; 16(4):379-97. PubMed ID: 10623366
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
13. Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer.
Biskupiak J; Oderda G; Brixner D; Tang D; Zacker C; Dalal AA
J Manag Care Spec Pharm; 2019 Aug; 25(8):859-866. PubMed ID: 31347980
[TBL] [Abstract][Full Text] [Related]
14. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
[TBL] [Abstract][Full Text] [Related]
16. Hyperuricemia in 2 Patients Receiving Palbociclib for Breast Cancer.
Bromberg DJ; Valenzuela M; Nanjappa S; Pabbathi S
Cancer Control; 2016 Jan; 23(1):59-60. PubMed ID: 27009458
[TBL] [Abstract][Full Text] [Related]
17. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.
Rugo HS; Finn RS; Gelmon K; Joy AA; Harbeck N; Castrellon A; Mukai H; Walshe JM; Mori A; Gauthier E; Lu DR; Bananis E; Martin M; Diéras V
Clin Breast Cancer; 2020 Apr; 20(2):e173-e180. PubMed ID: 31836434
[TBL] [Abstract][Full Text] [Related]
18. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Beauchemin C; Letarte N; Mathurin K; Yelle L; Lachaine J
J Med Econ; 2016 Jun; 19(6):619-29. PubMed ID: 26850287
[TBL] [Abstract][Full Text] [Related]
19. Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.
Bell T; Crown JP; Lang I; Bhattacharyya H; Zanotti G; Randolph S; Kim S; Huang X; Huang Bartlett C; Finn RS; Slamon D
Curr Med Res Opin; 2016 May; 32(5):959-65. PubMed ID: 26894413
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Finn RS; Crown JP; Ettl J; Schmidt M; Bondarenko IM; Lang I; Pinter T; Boer K; Patel R; Randolph S; Kim ST; Huang X; Schnell P; Nadanaciva S; Bartlett CH; Slamon DJ
Breast Cancer Res; 2016 Jun; 18(1):67. PubMed ID: 27349747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
